Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development.

Cleary Y, Gertz M, Morcos PN, Yu L, Youdim K, Phipps A, Fowler S, Parrott N.

Clin Pharmacol Ther. 2018 Sep;104(3):505-514. doi: 10.1002/cpt.956. Epub 2017 Dec 27.

PMID:
29226313
2.

In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes.

Nakagawa T, Fowler S, Takanashi K, Youdim K, Yamauchi T, Kawashima K, Sato-Nakai M, Yu L, Ishigai M.

Xenobiotica. 2018 Jun;48(6):546-554. doi: 10.1080/00498254.2017.1344910. Epub 2017 Jul 21.

PMID:
28657423
3.

Optimum designs for non-linear mixed effects models in the presence of covariates.

Bogacka B, Latif MAHM, Gilmour SG, Youdim K.

Biometrics. 2017 Sep;73(3):927-937. doi: 10.1111/biom.12660. Epub 2017 Jan 28.

PMID:
28131108
4.

Minimizing DILI risk in drug discovery - A screening tool for drug candidates.

Schadt S, Simon S, Kustermann S, Boess F, McGinnis C, Brink A, Lieven R, Fowler S, Youdim K, Ullah M, Marschmann M, Zihlmann C, Siegrist YM, Cascais AC, Di Lenarda E, Durr E, Schaub N, Ang X, Starke V, Singer T, Alvarez-Sanchez R, Roth AB, Schuler F, Funk C.

Toxicol In Vitro. 2015 Dec 25;30(1 Pt B):429-37. doi: 10.1016/j.tiv.2015.09.019. Epub 2015 Sep 25.

PMID:
26407524
5.

Reaction phenotyping: advances in the experimental strategies used to characterize the contribution of drug-metabolizing enzymes.

Zientek MA, Youdim K.

Drug Metab Dispos. 2015 Jan;43(1):163-81. doi: 10.1124/dmd.114.058750. Epub 2014 Oct 8. Review.

PMID:
25297949
6.

Simultaneous determination of multiple CYP inhibition constants using a cocktail-probe approach.

Zientek M, Youdim K.

Methods Mol Biol. 2013;987:11-23. doi: 10.1007/978-1-62703-321-3_2.

PMID:
23475664
7.

Application of PBPK modelling in drug discovery and development at Pfizer.

Jones HM, Dickins M, Youdim K, Gosset JR, Attkins NJ, Hay TL, Gurrell IK, Logan YR, Bungay PJ, Jones BC, Gardner IB.

Xenobiotica. 2012 Jan;42(1):94-106. doi: 10.3109/00498254.2011.627477. Epub 2011 Oct 30.

PMID:
22035569
8.

Optimum design of experiments for enzyme inhibition kinetic models.

Bogacka B, Patan M, Johnson PJ, Youdim K, Atkinson AC.

J Biopharm Stat. 2011 May;21(3):555-72. doi: 10.1080/10543406.2010.489979.

PMID:
21442525
9.

In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase.

Zientek M, Jiang Y, Youdim K, Obach RS.

Drug Metab Dispos. 2010 Aug;38(8):1322-7. doi: 10.1124/dmd.110.033555. Epub 2010 May 5.

PMID:
20444863
10.

Potential application of D-optimal designs in the efficient investigation of cytochrome P450 inhibition kinetic models.

Youdim KA, Atkinson AC, Patan M, Bogacka B, Johnson PJ.

Drug Metab Dispos. 2010 Jul;38(7):1019-23. doi: 10.1124/dmd.110.033142. Epub 2010 Apr 16.

PMID:
20400659
11.

A review of LC-MS techniques and high-throughput approaches used to investigate drug metabolism by cytochrome P450s.

Youdim KA, Saunders KC.

J Chromatogr B Analyt Technol Biomed Life Sci. 2010 May 15;878(17-18):1326-36. doi: 10.1016/j.jchromb.2010.02.013. Epub 2010 Feb 17. Review.

PMID:
20207203
12.

Comparison between recombinant P450s and human liver microsomes in the determination of cytochrome P450 Michaelis-Menten constants.

Youdim K, Dodia R.

Xenobiotica. 2010 Apr;40(4):235-44. doi: 10.3109/00498250903568504.

PMID:
20105059
13.

Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction.

Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, Dickins M, Phipps A, Darekar A, Hyland R, Obach RS.

Drug Metab Dispos. 2009 Aug;37(8):1658-66. doi: 10.1124/dmd.108.026252. Epub 2009 Apr 30.

PMID:
19406954
14.

Cytochrome P450 metabolism and inhibition: analysis for drug discovery.

Jones BC, Middleton DS, Youdim K.

Prog Med Chem. 2009;47:239-63. doi: 10.1016/S0079-6468(08)00206-3. Review. No abstract available.

PMID:
19328293
15.

An automated, high-throughput, 384 well Cytochrome P450 cocktail IC50 assay using a rapid resolution LC-MS/MS end-point.

Youdim KA, Lyons R, Payne L, Jones BC, Saunders K.

J Pharm Biomed Anal. 2008 Sep 10;48(1):92-9. doi: 10.1016/j.jpba.2008.05.011. Epub 2008 May 17.

PMID:
18584988
16.

Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction.

Youdim KA, Zayed A, Dickins M, Phipps A, Griffiths M, Darekar A, Hyland R, Fahmi O, Hurst S, Plowchalk DR, Cook J, Guo F, Obach RS.

Br J Clin Pharmacol. 2008 May;65(5):680-92. doi: 10.1111/j.1365-2125.2007.03070.x. Epub 2008 Feb 14.

17.

The time to move cytochrome p450 induction into mainstream pharmacology is long overdue.

Smith DA, Dickins M, Fahmi OA, Iwasaki K, Lee C, Obach RS, Padbury G, De Morais SM, Ripp SL, Stevens J, Voorman R, Youdim K.

Drug Metab Dispos. 2007 Apr;35(4):697-8. No abstract available.

PMID:
17384203
18.

Induction of cytochrome P450: assessment in an immortalized human hepatocyte cell line (Fa2N4) using a novel higher throughput cocktail assay.

Youdim KA, Tyman CA, Jones BC, Hyland R.

Drug Metab Dispos. 2007 Feb;35(2):275-82. Epub 2006 Nov 15.

PMID:
17108058
20.

The reaction of flavanols with nitrous acid protects against N-nitrosamine formation and leads to the formation of nitroso derivatives which inhibit cancer cell growth.

Lee SY, Munerol B, Pollard S, Youdim KA, Pannala AS, Kuhnle GG, Debnam ES, Rice-Evans C, Spencer JP.

Free Radic Biol Med. 2006 Jan 15;40(2):323-34. Epub 2005 Oct 11.

PMID:
16413414
21.

Flavonoids and the brain: interactions at the blood-brain barrier and their physiological effects on the central nervous system.

Youdim KA, Shukitt-Hale B, Joseph JA.

Free Radic Biol Med. 2004 Dec 1;37(11):1683-93. Review.

PMID:
15528027
22.

The flavone hispidulin, a benzodiazepine receptor ligand with positive allosteric properties, traverses the blood-brain barrier and exhibits anticonvulsive effects.

Kavvadias D, Sand P, Youdim KA, Qaiser MZ, Rice-Evans C, Baur R, Sigel E, Rausch WD, Riederer P, Schreier P.

Br J Pharmacol. 2004 Jul;142(5):811-20.

23.

Flavonoid permeability across an in situ model of the blood-brain barrier.

Youdim KA, Qaiser MZ, Begley DJ, Rice-Evans CA, Abbott NJ.

Free Radic Biol Med. 2004 Mar 1;36(5):592-604. Erratum in: Free Radic Biol Med. 2004 May 15;36(10):1342.

PMID:
14980703
24.

In vitro trans-monolayer permeability calculations: often forgotten assumptions.

Youdim KA, Avdeef A, Abbott NJ.

Drug Discov Today. 2003 Nov 1;8(21):997-1003. Review.

PMID:
14643163
25.

Hesperetin glucuronide, a photoprotective agent arising from flavonoid metabolism in human skin fibroblasts.

Proteggente AR, Basu-Modak S, Kuhnle G, Gordon MJ, Youdim K, Tyrrell R, Rice-Evans CA.

Photochem Photobiol. 2003 Sep;78(3):256-61.

PMID:
14556312
26.

Interaction between flavonoids and the blood-brain barrier: in vitro studies.

Youdim KA, Dobbie MS, Kuhnle G, Proteggente AR, Abbott NJ, Rice-Evans C.

J Neurochem. 2003 Apr;85(1):180-92.

27.

Roles of vitamins E and C on neurodegenerative diseases and cognitive performance.

Martin A, Youdim K, Szprengiel A, Shukitt-Hale B, Joseph J.

Nutr Rev. 2002 Oct;60(10 Pt 1):308-26. Review.

PMID:
12392148
28.

Dietary flavonoids as potential neuroprotectants.

Youdim KA, Spencer JP, Schroeter H, Rice-Evans C.

Biol Chem. 2002 Mar-Apr;383(3-4):503-19. Review.

PMID:
12033439
29.
30.

Fruit polyphenolics and brain aging: nutritional interventions targeting age-related neuronal and behavioral deficits.

Galli RL, Shukitt-Hale B, Youdim KA, Joseph JA.

Ann N Y Acad Sci. 2002 Apr;959:128-32. Review.

PMID:
11976192
31.
32.

Antioxidant and pro-oxidant capacity of catecholamines and related compounds. Effects of hydrogen peroxide on glutathione and sphingomyelinase activity in pheochromocytoma PC12 cells: potential relevance to age-related diseases.

Sofic E, Denisova N, Youdim K, Vatrenjak-Velagic V, De Filippo C, Mehmedagic A, Causevic A, Cao G, Joseph JA, Prior RL.

J Neural Transm (Vienna). 2001;108(5):541-57.

PMID:
11459075
33.
34.

Polyphenolics enhance red blood cell resistance to oxidative stress: in vitro and in vivo.

Youdim KA, Shukitt-Hale B, MacKinnon S, Kalt W, Joseph JA.

Biochim Biophys Acta. 2000 Sep 1;1523(1):117-22.

PMID:
11099865
35.

Incorporation of the elderberry anthocyanins by endothelial cells increases protection against oxidative stress.

Youdim KA, Martin A, Joseph JA.

Free Radic Biol Med. 2000 Jul 1;29(1):51-60.

PMID:
10962205
36.

Essential fatty acids and the brain: possible health implications.

Youdim KA, Martin A, Joseph JA.

Int J Dev Neurosci. 2000 Jul-Aug;18(4-5):383-99. Review.

PMID:
10817922

Supplemental Content

Loading ...
Support Center